title: Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics.
abstract: Beta-lactam antibiotics display time-dependant pharmacodynamics whereby constant antibiotic concentrations rather than high peak concentrations are most likely to result in effective treatment of infections caused by susceptible bacteria. Continuous administration has been suggested as an alternative strategy, to conventional intermittent dosing, to optimise beta-lactam pharmacokinetic/pharmacodynamic (PK/PD) properties. With the availability of emerging data, we elected to systematically investigate the published literature describing the comparative PK/PD and clinical outcomes of beta-lactam antibiotics administered by continuous or intermittent infusion. We found that the studies have been performed in various patient populations including critically ill, cancer and cystic fibrosis patients. Available in vitro PK/PD data conclusively support the administration of beta-lactams via continuous infusion for maximizing bacterial killing from consistent attainment of pharmacodynamic end-points. In addition, clinical outcome data supports equivalence, even with the use of a lower dose by continuous infusion. However, the present clinical data is limited with small sample sizes common with insufficient power to detect advantages in favour of either dosing strategy. With abundant positive pre-clinical data as well as document in vivo PK/PD advantages, large multi-centre trials are needed to describe whether continuous administration of beta-lactams is truly more effective than intermittent dosing.
authors: School of Pharmacy, International Islamic University of Malaysia, Kuantan, Malaysia.
authors: Abdul-Aziz
authors: AA
authors: Mohd Hafiz
authors: C E
authors: CE
authors: Staatz
authors: C M J
authors: CM
authors: Kirkpatrick
authors: J
authors: J
authors: Lipman
authors: J A
authors: JA
authors: Roberts
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D002648:Child; D003422:Critical Care; D016638:Critical Illness; D003550:Cystic Fibrosis / Q000150:complications; D005334:Fever / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay; D007958:Leukocyte Count; D009369:Neoplasms / Q000150:complications; D012121:Respiration, Artificial; D016896:Treatment Outcome; D047090:beta-Lactams / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams